H. Lundbeck A/S (CPH: HLUN.A)

Market Cap	46.20B
Revenue (ttm)	20.67B
Net Income (ttm)	2.59B
Shares Out	n/a
EPS (ttm)	2.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Mar 21, 2024

Volume	110,929
Open	40.90
Previous Close	41.30
Day's Range	40.80 - 41.50
52-Week Range	27.10 - 41.70
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About H. Lundbeck

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat M...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1915
• Employees: 5,681
• Stock Exchange: Nasdaq Copenhagen
• Ticker Symbol: HLUN.A

Financial Performance

In 2023, H. Lundbeck's revenue was 19.91 billion, an increase of 9.13% compared to the previous year's 18.25 billion. Earnings were 2.29 billion, an increase of 19.52%.